# SMAD1

## Overview
SMAD1 is a gene that encodes the SMAD family member 1 protein, a critical intracellular signal transducer in the bone morphogenetic protein (BMP) signaling pathway, which is part of the transforming growth factor-beta (TGF-β) superfamily. The SMAD1 protein is characterized by its two conserved domains, MH1 and MH2, which are essential for DNA binding and protein-protein interactions, respectively. These domains facilitate the protein's role in regulating gene expression in response to BMP signals, influencing cellular processes such as growth, differentiation, and apoptosis (Hill2008Nucleocytoplasmic; Attisano2001Thesmads). Upon activation, SMAD1 is phosphorylated and forms complexes with SMAD4, translocating to the nucleus to modulate transcription of target genes (Dijke2004New; Ten2002Regulation). SMAD1 is vital for embryonic development and has been implicated in various diseases, including diabetic nephropathy, pulmonary arterial hypertension, and certain cancers, highlighting its significance in both normal physiology and pathological conditions (Wang2023SMAD; Veiga2020NGAL; Conidi2011Few).

## Structure
SMAD1 is a protein characterized by two conserved domains: the MH1 domain at the N-terminus and the MH2 domain at the C-terminus, separated by a proline-rich linker region (Attisano2001Thesmads). The MH1 domain is responsible for DNA binding and adopts an alpha/beta fold stabilized by a zinc atom. It interacts with DNA using a beta-hairpin structure that inserts into the major groove, forming specific hydrogen-bonding interactions with conserved residues (Chaikuad2016Structural). The MH1 domain of SMAD1 displays a more open conformation compared to other SMADs, such as SMAD3, and can form a domain-swapped dimer, which affects its interactions with DNA (Ruiz2021Unveiling; Chaikuad2016Structural).

The MH2 domain is highly conserved and is crucial for protein-protein interactions, particularly in forming complexes with other SMAD proteins and cofactors like MAN1 (Miyazono2018Structural). The SMAD1-MAN1 complex involves the MH2 domain binding through a hydrophobic surface, with specific residues contributing to the interaction (Miyazono2018Structural). SMAD1 can form homo-dimers with DNA, involving a helix swap between monomers, which is distinct from the monomeric binding observed in other SMADs (Ruiz2021Unveiling).

## Function
SMAD1 is a critical intracellular mediator in the bone morphogenetic protein (BMP) signaling pathway, which is part of the transforming growth factor-beta (TGF-β) superfamily. In healthy human cells, SMAD1 is primarily involved in regulating gene expression in response to BMP signals, influencing processes such as cell growth, differentiation, and apoptosis (Hill2008Nucleocytoplasmic; Attisano2001Thesmads). Upon activation by BMP type I receptors, SMAD1 is phosphorylated and forms complexes with SMAD4, translocating to the nucleus to regulate transcription of target genes (Dijke2004New; Ten2002Regulation).

SMAD1 contains conserved MH1 and MH2 domains, which facilitate DNA binding and protein interactions, essential for its role in signal transduction (Hill2008Nucleocytoplasmic). It also possesses a functional nuclear export signal (NES) in the MH2 domain, allowing it to shuttle between the nucleus and cytoplasm, a process crucial for maintaining appropriate concentrations of active SMAD1 in the nucleus (Ten2002Regulation; Hill2008Nucleocytoplasmic).

In the context of organismal outcomes, SMAD1 is vital for embryonic development, particularly in processes like cardiovascular development and left-right asymmetry, as evidenced by embryonic lethality in mice lacking SMAD1 (Conidi2011Few).

## Clinical Significance
Alterations in the expression of the SMAD1 gene have been implicated in several diseases. In the context of diabetic nephropathy (DN), particularly in patients with type 2 diabetes mellitus (DM2), increased expression of SMAD1 is associated with the early stages of DN. This upregulation is linked to renal fibrosis and glomerular disease, potentially serving as an early biomarker for DN before significant structural changes are detectable by traditional biochemical markers (Veiga2020NGAL).

In pulmonary arterial hypertension (PAH), genetic variations in SMAD1, such as a novel missense variant (c.8T>C, p.V3A), have been identified in idiopathic PAH patients. These mutations are considered an infrequent cause of the disease but highlight the genetic complexity of PAH and the potential contribution of SMAD1 mutations to disease susceptibility (Nasim2011Molecular).

In cancer, particularly haematological neoplasms, aberrant activation of the BMP2/SMAD pathway, including SMAD1, is linked to disease progression. Increased expression of SMAD1 is associated with shorter survival in chronic lymphocytic leukemia (CLL) patients, indicating its role in cancer prognosis (Wang2023SMAD). Additionally, in gastric cancer, high SMAD1 expression is linked to cisplatin resistance, affecting treatment outcomes (Wang2023SMAD).

## Interactions
SMAD1 is involved in various protein interactions that are crucial for its role in the BMP signaling pathway. It interacts with SIP1, a zinc finger/homeodomain repressor, through the MH2 domain. This interaction is dependent on the activation of SMAD1 by BMP type I receptors, such as ALK-6, and does not occur with latent SMAD1 (Verschueren1999SIP1). SIP1 also interacts with the MH2 domains of SMAD2 and SMAD5, suggesting that SIP1 is a common binding protein for these receptor-regulated SMADs (Verschueren1999SIP1).

SMAD1 forms complexes with MAN1, a nuclear envelope protein, through specific domains including the UHM domain and the N-terminal ULM. The SMAD1-MAN1 complex involves phosphorylated-state mimics of the MH2 domain of SMAD1, and the structure of this complex has been determined at a resolution of 2.85 Å (Miyazono2018Structural).

SMAD1 also interacts with CHIP, an E3 ubiquitin ligase, which may mediate its degradation, similar to the role of Smurf1. This interaction highlights the importance of ubiquitin-dependent protein degradation in regulating SMAD1 levels and activity (Li2005Specific). These interactions underscore SMAD1's role in modulating cellular responses through various signaling pathways.


## References


[1. (Hill2008Nucleocytoplasmic) Caroline S Hill. Nucleocytoplasmic shuttling of smad proteins. Cell Research, 19(1):36–46, December 2008. URL: http://dx.doi.org/10.1038/cr.2008.325, doi:10.1038/cr.2008.325. This article has 182 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/cr.2008.325)

[2. (Wang2023SMAD) Qi Wang, Fei Xiong, Guanhua Wu, Da Wang, Wenzheng Liu, Junsheng Chen, Yongqiang Qi, Bing Wang, and Yongjun Chen. Smad proteins in tgf-β signalling pathway in cancer: regulatory mechanisms and clinical applications. Diagnostics, 13(17):2769, August 2023. URL: http://dx.doi.org/10.3390/diagnostics13172769, doi:10.3390/diagnostics13172769. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/diagnostics13172769)

[3. (Nasim2011Molecular) Md. Talat Nasim, Takeshi Ogo, Mohammad Ahmed, Rebecca Randall, Hasnin M. Chowdhury, Katie M. Snape, Teisha Y. Bradshaw, Laura Southgate, Grace J. Lee, Ian Jackson, Graham M. Lord, J. Simon R. Gibbs, Martin R. Wilkins, Keiko Ohta-Ogo, Kazufumi Nakamura, Barbara Girerd, Florence Coulet, Florent Soubrier, Marc Humbert, Nicholas W. Morrell, Richard C. Trembath, and Rajiv D. Machado. Molecular genetic characterization of smad signaling molecules in pulmonary arterial hypertension. Human Mutation, 32(12):1385–1389, October 2011. URL: http://dx.doi.org/10.1002/humu.21605, doi:10.1002/humu.21605. This article has 226 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21605)

[4. (Dijke2004New) Peter ten Dijke and Caroline S Hill. New insights into tgf-β–smad signalling. Trends in Biochemical Sciences, 29(5):265–273, May 2004. URL: http://dx.doi.org/10.1016/j.tibs.2004.03.008, doi:10.1016/j.tibs.2004.03.008. This article has 953 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.tibs.2004.03.008)

[5. (Miyazono2018Structural) Ken-ichi Miyazono, Yosuke Ohno, Hikaru Wada, Tomoko Ito, Yui Fukatsu, Akira Kurisaki, Makoto Asashima, and Masaru Tanokura. Structural basis for receptor-regulated smad recognition by man1. Nucleic Acids Research, 46(22):12139–12153, October 2018. URL: http://dx.doi.org/10.1093/nar/gky925, doi:10.1093/nar/gky925. This article has 16 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gky925)

[6. (Chaikuad2016Structural) Apirat Chaikuad and Alex N. Bullock. Structural basis of intracellular tgf-β signaling: receptors and smads. Cold Spring Harbor Perspectives in Biology, 8(11):a022111, August 2016. URL: http://dx.doi.org/10.1101/cshperspect.a022111, doi:10.1101/cshperspect.a022111. This article has 93 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a022111)

[7. (Conidi2011Few) Andrea Conidi, Silvia Cazzola, Karen Beets, Kathleen Coddens, Clara Collart, Frederique Cornelis, Luk Cox, Debruyn Joke, Mariya P. Dobreva, Ruben Dries, Camila Esguerra, Annick Francis, Abdelilah Ibrahimi, Roel Kroes, Flore Lesage, Elke Maas, Ivan Moya, Paulo N.G. Pereira, Elke Stappers, Agata Stryjewska, Veronique van den Berghe, Liesbeth Vermeire, Griet Verstappen, Eve Seuntjens, Lieve Umans, An Zwijsen, and Danny Huylebroeck. Few smad proteins and many smad-interacting proteins yield multiple functions and action modes in tgfβ/bmp signaling in vivo. Cytokine &amp; Growth Factor Reviews, 22(5–6):287–300, October 2011. URL: http://dx.doi.org/10.1016/j.cytogfr.2011.11.006, doi:10.1016/j.cytogfr.2011.11.006. This article has 123 citations.](https://doi.org/10.1016/j.cytogfr.2011.11.006)

[8. (Ruiz2021Unveiling) Lidia Ruiz, Zuzanna Kaczmarska, Tiago Gomes, Eric Aragon, Carles Torner, Regina Freier, Blazej Baginski, Pau Martin-Malpartida, Natàlia de Martin Garrido, José. A. Marquez, Tiago N. Cordeiro, Radoslaw Pluta, and Maria J. Macias. Unveiling the dimer/monomer propensities of smad mh1-dna complexes. Computational and Structural Biotechnology Journal, 19:632–646, 2021. URL: http://dx.doi.org/10.1016/j.csbj.2020.12.044, doi:10.1016/j.csbj.2020.12.044. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.csbj.2020.12.044)

[9. (Attisano2001Thesmads) Liliana Attisano and Si Tuen Lee-Hoeflich. The smads. Genome Biology, 2(8):reviews3010.1, 2001. URL: http://dx.doi.org/10.1186/gb-2001-2-8-reviews3010, doi:10.1186/gb-2001-2-8-reviews3010. This article has 295 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/gb-2001-2-8-reviews3010)

[10. (Ten2002Regulation) Peter Ten Dijke, Marie‐José Goumans, Fumiko Itoh, and Susumu Itoh. Regulation of cell proliferation by smad proteins. Journal of Cellular Physiology, 191(1):1–16, February 2002. URL: http://dx.doi.org/10.1002/jcp.10066, doi:10.1002/jcp.10066. This article has 346 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.10066)

[11. (Veiga2020NGAL) Glaucia Veiga, Beatriz Alves, Matheus Perez, Luiz Vinicius Alcantara, Joyce Raimundo, Lysien Zambrano, Jessica Encina, Edimar Cristiano Pereira, Marcelo Bacci, Neif Murad, and Fernando Fonseca. Ngal and smad1 gene expression in the early detection of diabetic nephropathy by liquid biopsy. Journal of Clinical Pathology, 73(11):713–721, March 2020. URL: http://dx.doi.org/10.1136/jclinpath-2020-206494, doi:10.1136/jclinpath-2020-206494. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1136/jclinpath-2020-206494)

[12. (Li2005Specific) Ren-Feng Li, Fan Zhang, Ying-Jie Lu, and Sen-Fang Sui. Specific interaction between smad1 and chip: a surface plasmon resonance study. Colloids and Surfaces B: Biointerfaces, 40(3–4):133–136, February 2005. URL: http://dx.doi.org/10.1016/j.colsurfb.2004.10.013, doi:10.1016/j.colsurfb.2004.10.013. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.colsurfb.2004.10.013)

[13. (Verschueren1999SIP1) Kristin Verschueren, Jacques E. Remacle, Clara Collart, Harry Kraft, Betty S. Baker, Przemko Tylzanowski, Luc Nelles, Gunther Wuytens, Ming-Tsan Su, Rolf Bodmer, James C. Smith, and Danny Huylebroeck. Sip1, a novel zinc finger/homeodomain repressor, interacts with smad proteins and binds to 5′-cacct sequences in candidate target genes. Journal of Biological Chemistry, 274(29):20489–20498, July 1999. URL: http://dx.doi.org/10.1074/jbc.274.29.20489, doi:10.1074/jbc.274.29.20489. This article has 395 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.274.29.20489)